Investigational Drug Information for Saroglitazar
✉ Email this page to a colleague
What is the drug development status for Saroglitazar?
Saroglitazar is an investigational drug.
There have been 17 clinical trials for Saroglitazar.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 20th 2023.
The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Liver Diseases. The leading clinical trial sponsors are Zydus Therapeutics Inc., Zydus Discovery DMCC, and Command Hospital, India.
There are twelve US patents protecting this investigational drug and two hundred and seventy-eight international patents.
Summary for Saroglitazar
| US Patents | 12 |
| International Patents | 278 |
| US Patent Applications | 157 |
| WIPO Patent Applications | 153 |
| Japanese Patent Applications | 17 |
| Clinical Trial Progress | Phase 2 (2023-07-20) |
| Vendors | 37 |
Recent Clinical Trials for Saroglitazar
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities | Zydus Lifesciences Limited | Phase 4 |
| Saroglitazar Magnesium 4 mg for NASH in People Living With HIV in the US | Zydus Therapeutics Inc. | Phase 2 |
| Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis | Zydus Therapeutics Inc. | Phase 2/Phase 3 |
Clinical Trial Summary for Saroglitazar
Top disease conditions for Saroglitazar
Top clinical trial sponsors for Saroglitazar
US Patents for Saroglitazar
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Saroglitazar | ⤷ Sign Up | Fused triterpene compounds and uses thereof | PIRAMAL ENTERPRISES LIMITED (Mumbai, IN) | ⤷ Sign Up |
| Saroglitazar | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Saroglitazar | ⤷ Sign Up | Combination | GENESIS PHARMA SA (Athens, GR) | ⤷ Sign Up |
| Saroglitazar | ⤷ Sign Up | Monocyclic compound | Takeda Pharmaceutical Company Limited (Osaka, JP) | ⤷ Sign Up |
| Saroglitazar | ⤷ Sign Up | FXR (NR1H4) modulating compounds | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign Up |
| Saroglitazar | ⤷ Sign Up | Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions | Eiger Group International, Inc. (Palo Alto, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Saroglitazar
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Saroglitazar | Argentina | AR097067 | 1989-12-31 | ⤷ Sign Up |
| Saroglitazar | Australia | AU2014294548 | 1989-12-31 | ⤷ Sign Up |
| Saroglitazar | Brazil | BR112015031878 | 1989-12-31 | ⤷ Sign Up |
| Saroglitazar | Canada | CA2917923 | 1989-12-31 | ⤷ Sign Up |
| Saroglitazar | China | CN105407873 | 1989-12-31 | ⤷ Sign Up |
| Saroglitazar | Eurasian Patent Organization | EA201690072 | 1989-12-31 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
